The pension fund leading the case nearly doubled the settlement price from $35 million after the Food and Drug Administration’s Center for Drug Evaluation and Research last month proposed withdrawing regulatory approval for the drug sold as Tavneos, finding it hasn’t shown to be effective and that the drugmaker’s application contained untrue statements. The fund sought Judge
If approved in the US District ...